Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:24:29 EDT Wed 08 May 2024
Enter Symbol
or Name
USA
CA



Q:LYRA - LYRA THERAPEUTICS INC - https://lyratherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LYRA - Q5.10.404·0.44930.10.42-0.1015-19.519,050.87,22917,5050.44  0.49  0.416.79  0.3619:58:29May 0615 min RT 2¢

Recent Trades - Last 10 of 17505
Time ETExPriceChangeVolume
19:58:29Q0.4051-0.11641,000
19:56:58Q0.404-0.11751,429
19:54:56Q0.4051-0.1164500
19:52:43Q0.4184-0.103123
19:52:33Q0.4051-0.1164200
19:52:13Q0.404-0.11752,619
19:52:10Q0.404-0.1175311
19:46:13Q0.409-0.1125200
19:45:23Q0.404-0.1175415
19:43:27Q0.4061-0.11542

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-06 07:59U:LYRANews ReleaseLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
2024-04-30 16:04U:LYRANews ReleaseLyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-26 16:51U:LYRANews ReleaseLyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-21 16:01U:LYRANews ReleaseLyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-03-01 16:01U:LYRANews ReleaseLyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 16:01U:LYRANews ReleaseLyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-07 07:00U:LYRANews ReleaseLyra Therapeutics to Participate in Upcoming Investor Conferences
2023-10-16 07:00U:LYRANews ReleaseLyra Therapeutics Announces Appointment of Ronan O ¢ € ™Brien as Chief Legal Officer
2023-09-12 07:00U:LYRANews ReleaseLyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
2023-09-06 08:00U:LYRANews ReleaseLyra Therapeutics to Participate in Upcoming Investor Conferences
2023-08-29 07:00U:LYRANews ReleaseLyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
2023-08-08 16:01U:LYRANews ReleaseLyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-13 07:30U:LYRANews ReleaseLyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
2023-06-02 16:01U:LYRANews ReleaseLyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-02 07:30U:LYRANews ReleaseLyra Therapeutics to Present at Jefferies Healthcare Conference
2023-06-01 07:29U:LYRANews ReleaseLyra Therapeutics Announces Closing of $50.0 Million Private Placement
2023-05-26 07:58U:LYRANews ReleaseLyra Therapeutics Announces $50.0 Million Private Placement
2023-05-12 07:00U:LYRANews ReleaseLyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-09 16:01U:LYRANews ReleaseLyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference